Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 153 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Follow-Up Questions
Molecular Partners AG のCEOは誰ですか？
Dr. Patrick Amstutz は Molecular Partners AG の Chief Executive Officer で、2006 から在籍しています。
MLLCF の株価パフォーマンスは？
MLLCF の現在の価格は $3.5 で、最終取引日から 0% decreased 変動しました。
Molecular Partners AG の主な事業テーマや業界は？
Molecular Partners AG は Biotechnology 業界、セクターは Health Care に属しています。
